Core Viewpoint - The recent stock placement by 和铂医药-B (02142) has been successfully completed, with significant participation from shareholders and a notable market value involved [1] Group 1: Stock Placement Details - On September 5, shareholders of 和铂医药-B deposited shares into Standard Chartered Bank (Hong Kong), with a total market value of 721 million HKD, representing 5.32% of the company [1] - The placement agreement's terms and conditions have been fulfilled, and the placement was completed on September 5, 2025 [1] - The placement agent successfully sold 45.022 million shares at a placement price of 11.50 HKD per share to no fewer than six subscribers [1]

Core Viewpoint - The recent stock placement by 和铂医药-B (02142) has been successfully completed, with significant participation from shareholders and a notable market value involved [1]. Group 1: Stock Placement Details - On September 5, shareholders of 和铂医药-B deposited shares into Standard Chartered Bank (Hong Kong), with a total market value of 721 million HKD, representing 5.32% of the company [1]. - The placement agreement's conditions have been met, and the placement was completed on September 5, 2025 [1]. - The placement agent successfully sold 45.022 million shares at a placement price of 11.50 HKD per share to no fewer than six subscribers [1].

Group 1 - The company, He Bo Pharmaceutical-B (02142), announced the issuance of a total of 280,200 shares between September 1 and September 5, 2025 [1] - On September 5, 2025, the company will issue 45,022,000 shares according to the placement agreement dated August 29, 2025 [1]

Group 1 - The company, Heptagon Pharmaceuticals-B (02142), announced the issuance of a total of 280,200 shares under the share scheme from September 1 to September 5, 2025 [1] - On September 5, 2025, the company will issue 45,022,000 shares according to the placement agreement dated August 29, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年9月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股 ...

Group 1 - The company, Heptagon Pharmaceuticals-B (02142), announced that all conditions for the placement have been met and the placement was completed on September 5, 2025 [1] - According to the terms and conditions of the placement agreement, the placement agent successfully placed 45.022 million shares at a price of HKD 11.50 per share to no fewer than six subscribers [1]

Group 1 - The company, Heptagon Pharmaceuticals-B (02142.HK), announced the completion of a placement of 45.022 million shares at a price of HKD 11.50 per share on September 5, 2025 [1] - The placement was successfully executed with at least six subscribers [1] - The company also granted 843,000 stock options and 3.282 million shares as incentives [2]

Group 1 - The core point of the article is that Heptagon Pharmaceuticals-B (02142) has successfully completed a placement of shares, fulfilling all conditions outlined in the placement agreement [1] - The placement involved the successful allocation of 45.022 million shares at a price of HKD 11.50 per share to no fewer than six subscribers [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告或其任何文本概不得直接或間接在美國，或在發放或派發本公告屬違法的任何其他司法 權區內發放或派發。 本公告並不構成在美國購買或認購證券的任何要約或招攬，亦不構成其任何一部分。本公告提 及的證券並無且將不會根據《1933年美國證券法》（「美國證券法」）登記，且不得在美國提呈發 售或出售，惟根據美國證券法的規定進行登記，或適用豁免登記，或進行毋須遵守有關登記規 定的交易則除外。本公司無意按照美國證券法於美國登記本公告所述任何證券，亦無意於美國 公開發售證券。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 完成根據一般授權配售新股 獨家整體協調人及獨家配售代理 ݷ 據董事作出一切合理查詢後所深知、盡悉及確信，承配人及彼等各自的最終實益 擁有人均為屬獨立於本公司及其 ...

Group 1: Market Overview - The Hang Seng Index rose by 0.62%, while the Hang Seng Tech Index increased by 0.82%, with a total turnover of HKD 124.6 billion in the morning session [1] - The Hang Seng Biotechnology Index surged by 3.1%, driven by optimism in the innovative drug sector ahead of the 2025 World Lung Cancer Conference, indicating potential for valuation recovery [1] Group 2: Company Performances - Three-Six Pharmaceutical (01530) saw a significant increase of 9.6% [1] - Hengrui Medicine-B (02142) rose by 5.82% [1] - Hutchison China MediTech (00013) increased by 6% [1] - United Laboratories (03933) gained 5% [1] - WuXi Biologics (02269) rose by 4.17% [1] Group 3: Other Notable Stocks - Chow Tai Fook (06168) surged over 13% as the gold consumption market enters a peak season, with expectations of inclusion in the Hong Kong Stock Connect [2] - FunPlus (09890) increased by over 5% after completing a name change and upgrading its overseas brand integration, with a higher proportion of overseas revenue in the first half [2] - Lehua Entertainment (02306) rose by 16%, with a nearly 90% year-on-year increase in interim profit attributable to shareholders, expanding monetization channels for its trendy IP [3] - UBTECH Robotics (09880) increased by 3%, with humanoid robot orders reaching CNY 400 million and securing a USD 1 billion strategic investment from a Middle Eastern fund [4] - Mobi Development (01860) surged over 12%, hitting a historical high with a cumulative increase of over 110% this year [5] - Goldwind Technology (02208) rose over 10%, reaching a new high as the wind power sector experiences accelerated growth, leading the industry in gross margin improvement [5] - Zhongshen Jianye (02503) experienced a significant drop, falling over 74% to a historical low, with a loss of CNY 11.81 million in the first half [5]